A phase II study of the combination of fixed dose rate gemcitabine, infusional 5 fluorouracil and bevacizumab in patients with advanced pancreas cancer.
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2011
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 03 Nov 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
- 03 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jan 2008 Planned end date added (Dec 2009) as reported by ClinicalTrials.gov.